DK0792160T3 - Glial-afledt neurofoisk faktor som et neurobeskyttende middel - Google Patents

Glial-afledt neurofoisk faktor som et neurobeskyttende middel

Info

Publication number
DK0792160T3
DK0792160T3 DK95935548T DK95935548T DK0792160T3 DK 0792160 T3 DK0792160 T3 DK 0792160T3 DK 95935548 T DK95935548 T DK 95935548T DK 95935548 T DK95935548 T DK 95935548T DK 0792160 T3 DK0792160 T3 DK 0792160T3
Authority
DK
Denmark
Prior art keywords
glial
derived
factor
neurophysical
gdnf
Prior art date
Application number
DK95935548T
Other languages
English (en)
Inventor
David Martin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK0792160T3 publication Critical patent/DK0792160T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK95935548T 1994-11-15 1995-11-13 Glial-afledt neurofoisk faktor som et neurobeskyttende middel DK0792160T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34082194A 1994-11-15 1994-11-15
PCT/IB1995/001004 WO1996014861A1 (en) 1994-11-15 1995-11-13 Glial derived neurotrophic factor as a neuroprotective agent

Publications (1)

Publication Number Publication Date
DK0792160T3 true DK0792160T3 (da) 2001-11-19

Family

ID=23335068

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95935548T DK0792160T3 (da) 1994-11-15 1995-11-13 Glial-afledt neurofoisk faktor som et neurobeskyttende middel

Country Status (13)

Country Link
US (1) US5733875A (da)
EP (1) EP0792160B1 (da)
JP (1) JPH10508839A (da)
AT (1) ATE205088T1 (da)
AU (1) AU691349B2 (da)
CA (1) CA2204911C (da)
DE (1) DE69522578T2 (da)
DK (1) DK0792160T3 (da)
ES (1) ES2159647T3 (da)
IL (1) IL115966A (da)
PT (1) PT792160E (da)
WO (1) WO1996014861A1 (da)
ZA (1) ZA959714B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
WO1997019693A1 (en) * 1995-11-29 1997-06-05 Amgen Inc. Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
ES2293662T3 (es) * 1996-11-15 2008-03-16 Genentech, Inc. Purificacion de neurotrofinas.
US6277820B1 (en) 1998-04-09 2001-08-21 Genentech, Inc. Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
WO2001030375A2 (en) * 1999-10-29 2001-05-03 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Use of gdnf for treating corneal defects
US20040197900A1 (en) * 2003-04-04 2004-10-07 Arnon Rosenthal Foggy
WO2007127803A2 (en) * 2006-04-25 2007-11-08 The Regents Of The University Of California Administration of growth factors for the treatment of cns disorders
US20070259031A1 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2014152511A1 (en) 2013-03-15 2014-09-25 The Jackson Laboratory Methods for promoting wound healing and hair growth
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP3538560B1 (en) 2016-11-10 2026-04-08 Keros Therapeutics, Inc. Gdnf fusion polypeptides and methods of use thereof
EP3973979A1 (en) * 2020-09-25 2022-03-30 The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth A tight junction (zonulae occludentes) protein for use in treating or preventing epilepsy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9205293A (es) * 1991-09-20 1993-05-01 Syntex Sinergen Neuroscience J Factores neurotrofico derivado del glial
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.

Also Published As

Publication number Publication date
DE69522578D1 (de) 2001-10-11
DE69522578T2 (de) 2002-07-11
ZA959714B (en) 1997-10-15
EP0792160B1 (en) 2001-09-05
IL115966A0 (en) 1996-01-31
IL115966A (en) 1999-11-30
AU691349B2 (en) 1998-05-14
ATE205088T1 (de) 2001-09-15
PT792160E (pt) 2002-02-28
CA2204911C (en) 2002-07-23
AU3752895A (en) 1996-06-06
CA2204911A1 (en) 1996-05-23
ES2159647T3 (es) 2001-10-16
JPH10508839A (ja) 1998-09-02
EP0792160A1 (en) 1997-09-03
WO1996014861A1 (en) 1996-05-23
US5733875A (en) 1998-03-31

Similar Documents

Publication Publication Date Title
DK0792160T3 (da) Glial-afledt neurofoisk faktor som et neurobeskyttende middel
EP0830369A4 (en) NOR-PREGNANE FOR INDUCING HYPOTHALAMIC EFFECTS
CA2098076A1 (en) Imidate prodrugs of pharmaceutically useful anticonvulsant sulfamates
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
MX9207495A (es) Compuestos de tetrahidroisoquinolina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
HUP0003323A2 (hu) Vorikonazolt tartalmazó gyógyászati készítmények
DK0610595T3 (da) Sammensætning af L-DOPA-estere
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
MY119375A (en) Treatment of tinnitus using neuroprotective agents
MX9205466A (es) Procedimiento para la preparacion de un medicamento para la administracion oral o topica en el tratamiento de leishmaniasis
DE69631609D1 (en) Tricyclische erythromycinderivate
MA26690A1 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1,2-a ] PYRAZINE ET PROCEDE POUR LEUR PREPARATION
YU49215B (sh) Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja
BG104434A (en) 2-halo-6-o-substituted ketolide derivatives
IL97796A0 (en) Pharmaceutical compositions containing n-alkylated 1,4-dihydropyridine-dicarboxylic acid esters,certain such compounds and their preparation
RU94046141A (ru) Замещенные производные /арилалкоксибензил/ аминопропанамида, способы их получения, фармацевтическая композиция
TW324662B (en) Benzamide-containing pharmaceutical composition
BR9814498A (pt) Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica
UA41285C2 (uk) Креатин фосфат і його фармацевтично прийнятні солі для лікування пухлин та фармацевтична композиція, що має протипухлинну активність
BR9809519A (pt) Sal, processo para fabricação e uso do mesmo, formulação farmacêutica, e, processo para prevenção ou tratamento de distúrbios cns e perturbações médicas relacionadas
WO1999045909A3 (en) Use of nitrone compounds for the inhibition of angiogenesis
CA2192822A1 (en) Use of immunosuppressive agents for the treatment of schizophrenia
AU6826700A (en) Ceramide analogs, process for their preparation and their use as antitumor agents
MY133438A (en) Morpholinobenzamide salts